DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS

Abstract

The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

Description

Claims

1-15. (canceled)

16. A dipeptidyl peptidase 3 (DPP3) binder wherein the binder is produced by a process comprising: injecting an animal with a DPP3-peptide or a conjugate comprising a DPP3-peptide,fusing activated B-cells from the animal after injection with a myeloma cell line and culturing the resulting cells,selecting and culturing cells expressing the binder,wherein said binder is defined as that which binds to an epitope according to SEQ ID NO.: 2, and binds to at least three amino acids of SEQ ID NO.: 2, wherein said epitope according to SEQ ID NO.: 2 is comprised in SEQ ID NO.: 1, and wherein said binder exhibits an affinity towards DPP3 at an affinity constant of at least 107 M-1.

17. The dipeptidyl peptidase 3 binder of claim 16, wherein said binder is binds to an epitope according to SEQ ID NO.: 3, and wherein said binder binds to at least three amino acids of SEQ ID NO.: 3.

18. The dipeptidyl peptidase 3 binder of claim 16, wherein said binder binds to an epitope according to SEQ ID NO.: 4, and wherein said DPP3 binder binds to at least three amino acids of SEQ ID NO.: 4.

19. The dipeptidyl peptidase 3 binder of claim 16, wherein said binder is selected from a group consisting of an antibody or antigen binding fragment or non-Ig scaffold.

20. The dipeptidyl peptidase 3 binder of claim 16, wherein said binder is selected from a group consisting of a monospecific antibody or a monospecific antigen binding fragment or a monospecific non-Ig scaffold.

21. A method of treatment comprising: administering the binder of claim 16 to a patient suffering from a disease or acute condition associated with oxidative stress.

22. The method of claim 21 wherein said disease or acute condition that is associated with oxidative stress is selected from a group consisting of neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic shock and SIRS.

23. The method of claim 22 wherein said neurodegenerative disease is selected from a group consisting of Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)),said metabolic syndrome is selected from a group consisting of insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes,said cardiovascular disorder is selected from a group consisting of aterosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction,said autoimmune disease is selected from a group consisting of rheumatoid arthritis, systemic lupus erythematosus,said inflammatory lung disease is selected from a group consisting of COPD, asthma,said kidney disease is selected from a group consisting of acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD),said liver disease is selected from a group consisting of viral hepatitis, and cirrhosis,said digestive disease is selected from a group consisting of inflammatory bowel disease e.g. Ulcerative colitis, Crohn’s disease, gastritis, pancreatitis and peptic ulcer,said viral infectious disease may be selected from a group consisting of blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus,said cancer is selected from a group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer,said inflammation is selected, andsaid sepsis, septic shock or SIRS is selected.

24. The method of claim 21 wherein said disease or acute condition that is associated with oxidative stress is selected from a group consisting of sepsis, septic shock, and SIRS.

25. The method of claim 21 wherein said disease or acute condition that is associated with oxidative stress is myocard.